This page explains where to look for ADPKD research, how to tell whether a study was done in people or in animals or cells, what clinical-trial phases mean, and what to do with what you find. It is a skill worth having whether you are following ADPKD because it is your own condition, or reading papers for a class or a science project. It provides background and vocabulary, not medical advice, and nothing you read here or anywhere else should change how you manage your health without talking to your care team first.

Where to look

  • PubMed is the main free search tool for biomedical and life-sciences papers. It holds tens of millions of citations and abstracts, including a great many on ADPKD.[1] Search autosomal dominant polycystic kidney disease and you will get thousands of results, so add a term for what you actually want: ADPKD adolescents, ADPKD tolvaptan, ADPKD gene editing. Filter by year, and by Free Full Text if you want to read more than the abstract.

    To be told about new papers rather than going back to check, make a free NCBI account. You sign in with a Google, Microsoft or ORCID account rather than creating another password. Once you are signed in, run your search, then click Create alert underneath the search box and choose how often you want the email, usually daily, weekly or monthly.[2] That is the closest thing to a research alert you can set up in five minutes.

  • ClinicalTrials.gov lists trials in people, including ones currently recruiting. It tells you what is being tested, on whom, where, and whether the trial is still open. ADPKD trials often have age rules, and some are limited to adults or exclude people under 18, which is worth knowing before you get your hopes up about one.
  • The PKD Foundation describes itself as the largest private funder of PKD research in the United States.[4] Its treatment pipeline shows what is in development and how far along it is, and it is one of the clearest public overviews of where PKD treatment research stands.

  • NIDDK is the part of the National Institutes of Health responsible for kidney disease. Its ADPKD pages explain the condition carefully and in plain language, and they are a good baseline for what ADPKD is and what its complications are.

    The NIDDK pages are also a good reminder to check dates. At the bottom of the ADPKD page is a line reading Last Reviewed January 2017.[5] The description of the disease has held up. The treatment section has not: it does not mention tolvaptan, which received FDA marketing approval in April 2018 to slow kidney-function decline in adults at risk of rapidly progressing ADPKD.[6] Government pages are careful, and careful is not the same as current.

Reading what you find

Most of what you find will not be about treating people yet. Check what kind of paper it is, too. A review explains what is known so far; an original research article reports a new study; a case report describes one person or family; and an editorial or commentary is someone's interpretation rather than a new experiment.

These are the labels that tell you the rest:

Preclinical means not in people. The study was done in cells, or in mice, or in both. Preclinical work is how every treatment begins, and most preclinical results do not become approved treatments. Both of those are true at the same time.

A mouse is not a person. Mouse models of ADPKD are bred to develop the disease quickly so it can be studied in months rather than decades. That is what makes them useful and also what makes them different from you.

A registered trial is not a successful trial. ClinicalTrials.gov lists trials that are not yet recruiting, recruiting, active, completed, terminated, withdrawn, or of unknown status.[3] Listing means someone is studying something, not that it worked.

Phases mean different things. Phase 1 mostly asks about safety, dose and side effects. Phase 2 looks for early evidence that a treatment does something, and keeps watching safety. Phase 3 studies larger groups to test whether it is effective and safe enough to compare with standard care or support approval. A phase 1 result is a long way from a pharmacy.[7]

Press releases are written to be shared. A university press office and the paper it describes can use quite different words for the same result. If a headline says reversed, cured, or breakthrough, find the study it links to and read what the researchers themselves claim.

Check the date, and check whether it is peer reviewed. Preprints are posted before other scientists have reviewed them. They are not worthless, but they are not finished either.

Questions worth asking

When you read about a new result, these four questions will tell you most of what you need:

  • Was this done in people, or in animals or cells?
  • If in people, how many, for how long, and were any of them teenagers?
  • Does the result apply to someone my age and at my stage, or only to people treated much earlier or later?
  • What do the researchers say is still unknown? Papers usually say this near the end, and it is often the most useful paragraph.

What this can feel like

Looking up research can feel strangely opposite from looking up ordinary information. You may start because you want a clear answer and end up with mouse studies, adult-only trials, paywalled abstracts, and words that sound more certain than they are.

That does not mean you are bad at this. It means research moves in steps, and most steps are not answers yet. A study can be exciting and still not be ready to change care. A headline can be hopeful and still skip the part where the paper says more research is needed.

If you feel disappointed, worried, or suddenly too hopeful after reading something, that is also information. Save the link, write down the question it raised, and bring it to someone who can help you put it in context.

When to bring in your care team

A paper is not a plan. Even a strong study cannot tell you what to do on its own, because it does not know your age, your kidney size, your blood pressure, what medication you take, what your family history looks like, or what your care team is already watching. Research can help you ask better questions. It cannot replace the people responsible for your care.

So bring what you find to your nephrologist rather than acting on it. If you have read something that worries you or gives you hope, say so at your next appointment and ask what they make of it. They will know whether a trial is relevant to you, and they will know things about your own situation that no paper can tell you.

Do not stop, start, or change any medication because of something you read. That includes anything on this site.

References

  1. National Library of Medicine. About PubMed. Available from: https://pubmed.ncbi.nlm.nih.gov/about/ [accessed September 12, 2026]
  2. National Center for Biotechnology Information. My NCBI Help: Saving and Managing Searches. Available from: https://www.ncbi.nlm.nih.gov/books/NBK53592/ [accessed September 12, 2026]
  3. ClinicalTrials.gov. Glossary of Common Site Terms. Available from: https://clinicaltrials.gov/study-basics/glossary [accessed September 12, 2026]
  4. PKD Foundation. About the Foundation. Available from: https://pkdcure.org/who-we-are/ [accessed September 12, 2026]
  5. National Institute of Diabetes and Digestive and Kidney Diseases. Autosomal Dominant Polycystic Kidney Disease. 2017 Jan. Available from: https://www.niddk.nih.gov/health-information/kidney-disease/polycystic-kidney-disease/autosomal-dominant-pkd [accessed September 12, 2026]
  6. U.S. Food and Drug Administration. Search Orphan Drug Designations and Approvals: tolvaptan (JYNARQUE). Marketing approval April 23, 2018. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=347311 [accessed September 12, 2026]
  7. National Institutes of Health. The Basics: Clinical Research Trials and You. Available from: https://www.nih.gov/health-information/nih-clinical-research-trials-you/basics [accessed September 12, 2026]